46 results on '"Karfis, Ioannis"'
Search Results
2. Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
3. Tumor Volume on PSMA PET as a Prognostic Biomarker in Prostate Cancer Patients Treated With Cabazitaxel
4. Suspicious cold thyroid nodule with intense focal 68Ga-DOTATATE uptake: a case report
5. 177Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors.
6. Radiopeptide Infusions of Hepatic Metastases After Temporal Implementation of an Intra-arterial Port System
7. Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [177Lu]Lu-DOTATATE in a panel of cancer cell lines
8. [18F]FDG PET/CT–Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
9. Prediction of177Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
10. [18F]FDG PET/CT–Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
11. A dosimetry procedure for organs-at-risk in 177Lu peptide receptor radionuclide therapy of patients with neuroendocrine tumours
12. PSMA PET/CT for Response Assessment and Overall Survival Prediction in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Androgen Receptor Pathway Inhibitors
13. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma
14. Low 68Ga–PSMA PET/CT Uptake in Chronic Intramuscular Nodular Fasciitis
15. Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE
16. Accuracy and precision assessment for activity quantification in individualized dosimetry of 177Lu-DOTATATE therapy
17. Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177Lu-DOTATATE.
18. Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
19. Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
20. Acute Pancreatitis Following Peptide Receptor Radionuclide Therapy: An Unusual Adverse Event
21. Disturbing the Redox Balance Using Buthionine Sulfoximine Radiosensitized Somatostatin Receptor-2 Expressing Pre-Clinical Models to Peptide Receptor Radionuclide Therapy with 177 Lu-DOTATATE.
22. Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score.
23. Quantitative PET Parameters for Outcome Prediction of Peptide Receptor Radionuclide Therapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
24. 68Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy
25. Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option
26. Targeted radionuclide therapy: an emerging field in solid tumours
27. A shining heart at Valentine's Day
28. Mantle cell lymphoma simulating inflammatory bowel disease.
29. Radiopeptide infusions of hepatic metastases after temporal implementation of an intra-arterial port system
30. Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias
31. 131I-metaiodobenzylguanidine and peptide receptor radionuclide therapy in pheochromocytoma and paraganglioma
32. Prognostic value of a three-scale grading system based on combining molecular imaging with 68Ga-DOTATATE and 18F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias
33. 68Ga-PSMA PET/CT for response assessment and outcome prediction in metastatic prostate cancer patients treated with taxane-based chemotherapy.
34. Low 68Ga–PSMA PET/CT Uptake in Chronic Intramuscular Nodular Fasciitis
35. How COVID-19 pandemic affected cancer progression: Three different scenarios evidenced by PET imaging.
36. Unusual diffuse liver 18F-FDG uptake in melanoma patient treated by ipilimumab
37. Ενδαρτηριακή θεραπευτική προσέγγιση ηπατικών, νευροενδοκρινούς χαρακτήρα, νεοπλασιών με 111Ινδιο-Πεντετριοτίδιο μετά από προσωρινή εγκατάσταση καθετήρα (Port)
38. Accuracy and precision assessment for activity quantification in individualized dosimetry of Lu-DOTATATE therapy.
39. 177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study.
40. [ 18 F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study.
41. Prediction of 177 Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study.
42. 68 Ga-PSMA PET/CT for Response Assessment and Outcome Prediction in Metastatic Prostate Cancer Patients Treated with Taxane-Based Chemotherapy.
43. Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option.
44. Prognostic value of a three-scale grading system based on combining molecular imaging with 68 Ga-DOTATATE and 18 F-FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasias.
45. Unusual diffuse liver 18 F-FDG uptake in melanoma patient treated by ipilimumab.
46. Myocardial bridge: an unusual cause of asymptomatic ST-elevation during treadmill stress test causing functional ischaemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.